News and Upcoming Events

The Association of Bioethics Program Directors (ABPD) has published the statement "Bioethics Guidance for the Post-Dobbs Landscape," offering healthcare ethics guidelines for health care providers, budgets, and policymakers moving forward in a post-Dobbs landscape, cross-referenced with some of the relevant expected harms and patients' needs. Center Director Sean Valles is among the co-authors of this statement. The ABPD comprises the leadership of nearly 100 academic bioethics programs at medical centers and universities across North America. Visit their website to read the full statement.

The Center is excited to welcome new faculty member Michelle T. Pham, PhD, who starts in August. Most recently Pham was a postdoctoral research fellow in the Center for Bioethics at Harvard Medical School, where she collaborated on multiple NIH-funded neuroethics projects. Visit our blog to learn more, and please join us in welcoming her to MSU.

Visit the College of Human Medicine's website to read an interview with Center Assistant Professor Jennifer McCurdy, PhD, stemming from her work on The Hastings Center special report "A Critical Moment in Bioethics: Reckoning with Anti-Black Racism Through Intergenerational Dialogue."

The Hastings Center has published a special report on "A Critical Moment in Bioethics: Reckoning with Anti‐Black Racism through Intergenerational Dialogue." The report includes contributions from Center faculty Jennifer McCurdy, PhD, Libby Bogdan-Lovis, and Karen Kelly-Blake, PhD. One of the editors of the report, Faith Fletcher, PhD, MA, is an alumna of our former MA program in Bioethics, Humanities, and Society. Visit our blog to learn more.

A recording of the March 24 Bioethics for Breakfast session on "Aducanumab, Alzheimer’s: Having That Conversation" is now available for viewing. The recording features College of Human Medicine faculty members Leonard M. Fleck, PhD, and Irving E. Vega, PhD. They offer their respective expertise and perspective on the controversial drug Aducanumab, which was approved by the FDA to treat Alzheimer’s disease. Visit our blog for a summary of the session.